TCC-Pan2Homo sapiens (Human)Cancer cell line

Also known as: TCCPAN2, TCC-PAN2

🤖 AI SummaryBased on 6 publications

Quick Overview

Pancreatic ductal adenocarcinoma cell line with metabolic subtypes and drug sensitivity profiles.

Detailed Summary

TCC-Pan2 is a human pancreatic ductal adenocarcinoma (PDAC) cell line derived from ascitic fluid of a 47-year-old female patient. It exhibits distinct metabolic subtypes, including glycolytic and lipogenic profiles, and shows differential sensitivity to metabolic inhibitors. The cell line has been used to develop an orthotopic peritoneal dissemination model for studying PDAC progression and therapeutic responses. TCC-Pan2 demonstrates anchorage-independent growth, expresses pancreatic tumor markers such as DUPAN-2 and SPan-1, and forms poorly differentiated adenocarcinomas in xenograft models. It also harbors mutations in KRAS and TP53, with amplification of KRAS and homozygous deletion of CDKN2A, reflecting genetic alterations seen in PDAC tumors. The cell line has been utilized to evaluate the efficacy of drugs like NK105 and paclitaxel in preclinical studies.

Research Applications

Metabolic profiling and drug sensitivity testingOrthotopic tumor model developmentGenomic and transcriptomic analysisImmunotherapy research

Key Characteristics

Anchorage-independent growthExpression of pancreatic tumor markers (DUPAN-2, SPan-1)Metabolic subtype diversity (glycolytic, lipogenic)KRAS and TP53 mutationsAmplification of KRAS and deletion of CDKN2A

Generated on 6/20/2025

Basic Information

Database ID	CVCL_3178
Species	Homo sapiens (Human)
Tissue Source	Ascites[UBERON:UBERON_0007795]

Donor Information

Age	47
Age Category	Adult
Sex	Female
Race	asian

Disease Information

Disease	Pancreatic ductal adenocarcinoma
Lineage	Pancreas
Subtype	Pancreatic Adenocarcinoma
OncoTree Code	PAAD

DepMap Information

Source Type	HSRRB
Source ID	ACH-000502_source

Known Sequence Variations

Type	Gene/Protein	Description	Zygosity	Note	Source
MutationSimple	TP53	c.993+1G>A (IVS9+1G>A)	Homozygous	Splice donor mutation	Unknown, PubMed=30747829
MutationSimple	KRAS	p.Gly12Arg (c.34G>C)	Unspecified	-	PubMed=26124327
Gene deletion	CDKN2A	-	Homozygous	Possible	PubMed=26870271

Haplotype Information (STR Profile)

Short Tandem Repeat (STR) profile for cell line authentication.

Amelogenin

CSF1PO

D13S317

D16S539

D18S51

D21S11

D3S1358

D5S818

11,13

D7S820

8,11

D8S1179

13,16

FGA

Penta D

Penta E

TH01

6,7

TPOX

11,12

vWA

Gene Expression Profile

Gene expression levels and statistical distribution

Loading cohorts...

Full DepMap dataset with combined data across cell lines

Loading gene expression data...

Publications

Establishment of highly invasive pancreatic cancer cell lines and the expression of IL-32.

Tanaka S., Nishida T., Hatta H., Nakajima T.

Oncol. Lett. 20:2888-2896(2020).

DOI PubMed PMC

Quantitative proteomics of the Cancer Cell Line Encyclopedia.";

Sellers W.R., Gygi S.P.

Cell 180:387-402.e16(2020).

DOI PubMed PMC

Comprehensive transcriptomic analysis of cell lines as models of primary tumors across 22 tumor types.

van 't Veer L.J., Butte A.J., Goldstein T., Sirota M.

Nat. Commun. 10:3574.1-3574.11(2019).

DOI PubMed PMC

Next-generation characterization of the Cancer Cell Line Encyclopedia.

Sellers W.R.

Nature 569:503-508(2019).

DOI PubMed PMC

An interactive resource to probe genetic diversity and estimated ancestry in cancer cell lines.

Dutil J., Chen Z.-H., Monteiro A.N.A., Teer J.K., Eschrich S.A.

Cancer Res. 79:1263-1273(2019).

DOI PubMed PMC

Development and biological analysis of a novel orthotopic peritoneal dissemination mouse model generated using a pancreatic ductal adenocarcinoma cell line.

Yokozaki H.

Pancreas 48:315-322(2019).

DOI PubMed PMC

TCLP: an online cancer cell line catalogue integrating HLA type, predicted neo-epitopes, virus and gene expression.

Loewer M., Sahin U., Castle J.C.

Genome Med. 7:118.1-118.7(2015).

DOI PubMed PMC

Metabolite profiling stratifies pancreatic ductal adenocarcinomas into subtypes with distinct sensitivities to metabolic inhibitors.

Manning G., Settleman J., Hatzivassiliou G., Evangelista M.

Proc. Natl. Acad. Sci. U.S.A. 112:E4410-E4417(2015).

DOI PubMed PMC

A resource for cell line authentication, annotation and quality control.

Neve R.M.

Nature 520:307-311(2015).

DOI PubMed

A comprehensive transcriptional portrait of human cancer cell lines.

Settleman J., Seshagiri S., Zhang Z.-M.

Nat. Biotechnol. 33:306-312(2015).

DOI PubMed

The Cancer Cell Line Encyclopedia enables predictive modelling of anticancer drug sensitivity.

Morrissey M.P., Sellers W.R., Schlegel R., Garraway L.A.

Nature 483:603-607(2012).

DOI PubMed PMC